These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36748936)

  • 21. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
    Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
    Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Craniopharyngioma in Pediatrics and Adults.
    Piloni M; Gagliardi F; Bailo M; Losa M; Boari N; Spina A; Mortini P
    Adv Exp Med Biol; 2023; 1405():299-329. PubMed ID: 37452943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapies in the medical management of craniopharyngioma.
    Iglesias P
    Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 25. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
    Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
    Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
    Martinez-Barbera JP
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
    Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
    Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
    Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
    Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
    Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
    Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
    [No Abstract]   [Full Text] [Related]  

  • 32. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
    Erfurth EM
    J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
    Apps JR; Martinez-Barbera JP
    Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
    Fujio S; Juratli TA; Takajo T; Arita K; Nagano Y; Yoshimoto K; Nayyar N; Curry WT; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):385-391. PubMed ID: 33967180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
    Campanini ML; Colli LM; Paixao BM; Cabral TP; Amaral FC; Machado HR; Neder LS; Saggioro F; Moreira AC; Antonini SR; de Castro M
    Horm Cancer; 2010 Aug; 1(4):187-96. PubMed ID: 21761366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary Biological Insights and Clinical Management of Craniopharyngioma.
    Apps JR; Muller HL; Hankinson TC; Yock TI; Martinez-Barbera JP
    Endocr Rev; 2023 May; 44(3):518-538. PubMed ID: 36574377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
    Cao J; Lin JP; Yang LX; Chen K; Huang ZS
    Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Craniopharyngiomas and odontogenic tumors mimic normal odontogenesis and share genetic mutations, histopathologic features, and molecular pathways activation.
    Gomes CC; de Sousa SF; Gomez RS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Mar; 127(3):231-236. PubMed ID: 30598409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.